恩替卡韦治疗HBeAg阴性代偿期慢性乙型肝炎肝硬化的效果分析

韩本丽

doi:10.3969/j.issn.1001-5256.2016.08.018

恩替卡韦治疗HBeAg阴性代偿期慢性乙型肝炎肝硬化的效果分析

DOI: 10.3969/j.issn.1001-5256.2016.08.018

韩本丽

襄阳市中医医院肝胆科

详细信息

中图分类号: R512.62;R575.2
计量
- 文章访问数: 2327
- HTML全文浏览量: 30
- PDF下载量: 462
- 被引次数: 0
出版历程
- 收稿日期: 2016-02-26
- 出版日期: 2016-08-20

Clinical efficacy of entecavir in HBeAg-negative chronic hepatitis B with compensated cirrhosis

Han BenLi

Department of Hepatobiliary,Xiangyang Hospital of Traditional Chinese Medicine

摘要

摘要: 目的探讨恩替卡韦（ETV）治疗HBe Ag阴性代偿期慢性乙型肝炎肝硬化患者96周的临床效果及其对不同HBV DNA载量患者的影响。方法选取2009年1月-2013年6月于襄阳市中医医院就诊的HBe Ag阴性代偿期慢性乙型肝炎肝硬化患者共118例,Child-Pugh评分为A级,根据HBV DNA载量分为高载量组（A组）:HBV DNA≥105拷贝/ml和低载量组（B组）:HBV DNA<105拷贝/ml。给予恩替卡韦0.5 mg/d治疗96周,所有患者治疗前后采用Child-Pugh评分评价肝功能,观察患者治疗前后ALT、白蛋白（Alb）、TBil变化。通过透明质酸、α2巨球蛋白、肝脏硬度测量值（LSM）评估肝纤维化情况。计量资料组间比较采用t检验,不同时间点组内和组间比较采用重复测量数据方差分析。计数资料组间比较采用χ2检验。结果两组血清ALT、Alb、TBil在治疗第12、24周显著下降（χ2值分别为9.241、6.428、11.134、5.139,P值均<0.05）,两组ALT复常率和HBV DNA阴转率在治疗第24、48周差异均具有统计学意义（t值分别为2.648、...
- 肝炎,乙型,慢性 /
- 肝炎e抗原,乙型 /
- 肝硬化 /
- 恩替卡韦 /
- 治疗
Abstract: Objective To investigate the clinical efficacy of 96- week entecavir( ETV) treatment for HBe Ag- negative chronic hepatitis B patients with compensated cirrhosis,as well as its effect on patients with different HBV DNA loads. Methods A total of 118 chronic hepatitis B patients with compensated cirrhosis who visited Xiangyang Hospital of Traditional Chinese Medicine from January 2009 to June 2013 were enrolled and all had Child- Pugh class A cirrhosis. According to HBV DNA load,these patients were divided into high- load group( group A,HBV DNA≥105copies / ml) and low- load group( group B,HBV DNA < 105 copies / ml). All the patients were treated with ETV 0. 5 mg / d for 96 weeks. Child- Pugh score was used to evaluate liver function before and after treatment,and the changes in alanine aminotransferase( ALT),albumin( Alb),and total bilirubin( TBil) after treatment were observed. Hyaluronic acid( HA),α2- macroglobulin,and liver stiffness measurement( LSM) were used to evaluate liver fibrosis. The t- test was used for comparison between groups,and a repeated- measures analysis of variance was used for comparison within one group and between groups at different time points. Chisquare test was applied for comparison of categorical data between the two groups. Results The two groups showed significant reductions in ALT,Alb,and TBil at weeks12 and 24 of treatment( all P < 0. 05),and the ALT normalization rate and HBV DNA clearance rate at weeks 24 and 48 of treatment showed significantly differences between the two groups( χ2= 9. 241,6. 428,11. 134,5. 139,all P < 0. 05). Both groups showed significant reductions in HA,α2- macroglobulin,and LSM after treatment( t = 2. 648,1. 921,4. 018,3. 166,2. 136,3. 461,all P < 0. 05). The incidence rates of complications such as variceal bleeding,ascites,and hepatocellular carcinoma showed no significant differences between the two groups( all P > 0.05). Conclusion In HBe Ag- negative chronic hepatitis B patients with compensated cirrhosis,ETV can significantly improve liver function,slow down the process of liver fibrosis and cirrhosis,and effectively reduce long- term complications.
- hepatitis B /
- chronic /
- hepatitis B e antigens /
- liver cirrhosis /
- entecavir

HTML全文

参考文献(15)

[1]GAO YZ,JIA SH,ZHAO LF,et al.Clinical efficacy of entecavir combined with Xinganbao capsules in treatment of liver cirrhosis among patients with chronic hepatitis B[J].J Clin Hepatol,2014,30(4):314-316.(in Chinese)高远征,贾素华,赵连峰,等.恩替卡韦联合心肝宝胶囊治疗慢性乙型肝炎肝硬化的疗效观察[J].临床肝胆病杂志,2014,30(4):314-316.

[2]LOK A,Mc MAHON BJ.Chronic hepatitis B:update 2009[J].Hepatology,2009,50(3):1-36.

[3]European Association for the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.

[4]LIAW YF,KAO JH,PIRATVISUTH T,et al.Asian-Pacific consensus statement onthe management of chronic hepatitis B:a 2012update[J].Hepatol Int,2012,6(4):531-561.

[5]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010版)[J].临床肝胆病杂志,2011,27(1):Ⅰ-ⅩⅥ.

[6]CHEN L,ZHOU XB,WEN DF,et al.Clinical features and liver pathology in chronic hepatitis B virus-infected patients with normal liver function[J].J Clin Hepatol,2015,31(9):1430-1433.(in Chinese)陈丽,周兴蓓,温丹凤,等.肝功能正常的慢性HBV感染者的临床特征及肝脏病理学分析[J].临床肝胆病杂志,2015,31(9):1430-1433.

[7]HUANG YN,WU H.Progress in the antiviral treatment of HBVrelated cirrhosis[J].Fudan Univ J Med Sci,2013,40(2):233-238.(in Chinese)黄英男,吴昊.乙型肝炎肝硬化抗病毒治疗研究进展[J].复旦学报:医学版,2013,40(2):233-238.

[8]WU Y,HAN L,YUAN YF,et al.Meta-analysis of telbivudine and lamivudine in the treatment of chronic hepatitis B[J].China Med Herald,2014,11(28):11-13,18.(in Chinese)吴岩,韩璐,原永芳,等.替比夫定和拉米夫定治疗慢性乙型肝炎的Meta分析[J].中国医药导报,2014,11(28):11-13,18.

[9]LIAW YF.Impact of therapy on the long term outcome of chronic hepatitis B[J].Clin Liver Dis,2013,17(3):413-423.

[10]MARCELLIN P,ASSELAH T.Long-term therapy for chronic hepatitis B:hepatitis B virus DNA suppression leading to cirrhosis reversal[J].J Gastroenterol Hepatol,2013,28(6):912-923.

[11]Chinese Society of Hepatology and Chinese Society of Infectious Diseases Chinese,Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.

[12]ZHANG YX,ZHANG JB.Clinical efficacy of modified prescription of pingweisini combined with entecavir on patients at decompensation stage of liver cirrhosis[J/CD].Chin J Liver Dis:Electronic Edition,2014,6(4):39-41.(in Chinese)张燕霞,张晋波.加减平胃四逆方联合恩替卡韦治疗乙型肝炎失代偿期肝硬化临床研究[J/CD].中国肝脏病杂志:电子版,2014,6(4):39-41.

[13]KUMADA T,TOYODA H,TADA T,et al.Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients:a propensity score analysis[J].J Hepatol,2013,58(3):427-433.

[14]CHANG ML,LIAW YF,HADZI YANNIS SJ.Systematic review:cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B[J].Aliment Pharmacol Ther,2015,42(3):243-257.

[15]KIM YJ,HO HC,SINN DH,et al.Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients[J].J Gastroenterol Hepatol,2012,27(2):306-312.

施引文献

资源附件(0)

访问统计